These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 30222798

  • 1. Letter to the Editor: Efficacy of the Intravitreal Sustained-Release Dexamethasone Implant for DME Refractory to Anti-VEGF Therapy: Meta-Analysis and Clinical Implications.
    Hennings C, Evans J, Mehta H.
    Ophthalmic Surg Lasers Imaging Retina; 2018 Sep 01; 49(9):654-655. PubMed ID: 30222798
    [No Abstract] [Full Text] [Related]

  • 2. Dexamethasone and Anti-VEGF Combination Therapy for the Treatment of Diabetic Macular Edema.
    Al-Khersan H, Hariprasad SM, Salehi-Had H.
    Ophthalmic Surg Lasers Imaging Retina; 2019 Jan 01; 50(1):4-7. PubMed ID: 30640389
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of the Intravitreal Sustained-Release Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-Vascular Endothelial Growth Factor Therapy: Meta-Analysis and Clinical Implications.
    Khan Z, Kuriakose RK, Khan M, Chin EK, Almeida DR.
    Ophthalmic Surg Lasers Imaging Retina; 2017 Feb 01; 48(2):160-166. PubMed ID: 28195619
    [Abstract] [Full Text] [Related]

  • 4. Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema.
    Aroney C, Fraser-Bell S, Lamoureux EL, Gillies MC, Lim LL, Fenwick EK.
    Invest Ophthalmol Vis Sci; 2016 Oct 01; 57(13):5541-5546. PubMed ID: 27768792
    [Abstract] [Full Text] [Related]

  • 5. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
    Hatz K, Ebneter A, Tuerksever C, Pruente C, Zinkernagel M.
    Ophthalmologica; 2018 Oct 01; 239(4):205-214. PubMed ID: 29402873
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema.
    Güler E, Totan Y, Betül Güragaç F.
    Cutan Ocul Toxicol; 2017 Jun 01; 36(2):180-184. PubMed ID: 28366074
    [Abstract] [Full Text] [Related]

  • 7. Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study).
    Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, Li J, Quin GJ, McAllister IL, Gillies MC.
    Ophthalmology; 2016 Jun 01; 123(6):1399-401. PubMed ID: 26783096
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
    Totan Y, Güler E, Gürağaç FB.
    Curr Eye Res; 2016 Jun 01; 41(1):107-13. PubMed ID: 25610946
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up Study.
    Comet A, Gascon P, Sauvan L, Donnadieu B, Matonti F.
    Acta Ophthalmol; 2019 Sep 01; 97(6):e937-e938. PubMed ID: 30741468
    [No Abstract] [Full Text] [Related]

  • 15. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
    Shin YU, Hong EH, Lim HW, Kang MH, Seong M, Cho H.
    BMC Ophthalmol; 2017 Oct 03; 17(1):182. PubMed ID: 28974211
    [Abstract] [Full Text] [Related]

  • 16. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C, Zur D, Fraser-Bell S, Laíns I, Santos AR, Lupidi M, Cagini C, Gabrielle PH, Couturier A, Mané-Tauty V, Giancipoli E, Ricci GD, Cebeci Z, Rodríguez-Valdés PJ, Chaikitmongkol V, Amphornphruet A, Hindi I, Agrawal K, Chhablani J, Loewenstein A, Iglicki M, Rehak M, International Retina Group.
    Acta Diabetol; 2018 Aug 03; 55(8):789-796. PubMed ID: 29730822
    [Abstract] [Full Text] [Related]

  • 17. Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants.
    García-Layana A, Figueroa MS, Arias L, Adán A, Cabrera F, Abraldes M, Fernández-Vega Á, Navarro R, Cervera E, Silva R, Armadá F, Donate J, Ruiz-Moreno JM.
    Ophthalmologica; 2018 Aug 03; 240(2):61-72. PubMed ID: 29617689
    [Abstract] [Full Text] [Related]

  • 18. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
    Kim M, Cho YJ, Lee CH, Lee SC.
    Eye (Lond); 2016 May 03; 30(5):718-25. PubMed ID: 26939558
    [Abstract] [Full Text] [Related]

  • 19. Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab.
    Joe AW, Wickremasinghe SS, Gillies MC, Nguyen V, Lim LL, Mehta H, Fraser-Bell S.
    Clin Exp Ophthalmol; 2019 Mar 03; 47(2):287-289. PubMed ID: 30084193
    [No Abstract] [Full Text] [Related]

  • 20. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach.
    Giovannini A, Parravano M, Ricci F, Bandello F.
    Eur J Ophthalmol; 2019 Jan 03; 29(1):82-91. PubMed ID: 29882421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.